Bertin Pharma, a subsidiary of Bertin Technologies specializing in services for pharmaceutical R & D, announced on Wednesday that it has entered into "exclusive negotiations" for the sale of its pharmaceutical and biotech services business to two French companies specialized in the field.
Bertin Pharma, which belongs to the industrial plant manufacturer CNIM, "entered into exclusive negotiations with Amatsigroup for the sale of its pharmaceutical development activities (...) and with the Oncodesign group for the sale of its pre-clinical and clinical studies at other sites, "she said in a statement.
Activities related to the provision of bioanalytical tools and biological reagents for defense and life sciences are maintained within Bertin Pharma, she said, underlining that the project could be finalized during the summer 2017.
"With this proposed sale of service activities in the pharma / biotech sector, the CNIM Group intends to focus on strategic lines more in line with its industrial core business in the field of energy, the environment, of defense and security, "he explained.
Bertin Pharma, located in the Ile-de-France, Center and Aquitaine regions, employs 125 people and generates a turnover of 16 million euros.